A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Time to First Occurrence of Composite Endpoint of Major Cardiovascular and Kidney Events

Composite endpoint includes nonfatal myocardial infarction, nonfatal stroke, hospitalization or urgent visit due to heart failure, coronary revascularization, ≥40% sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, or all-cause death

Time frame: Baseline up to end of study (about 5 years)

Change from Baseline in Total eGFR Slope

Time frame: Baseline up to end of study (about 5 years)

Time to Onset of Type 2 Diabetes

Time frame: Baseline up to end of study (about 5 years)